-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Ptc Therapeutics, Inc. annual/quarterly Deferred Income Tax Expense (Benefit) history and growth rate from 2014 to 2024.
- Ptc Therapeutics, Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$1K, a 75% increase year-over-year.
- Ptc Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was -$55.9M, a 19.1% decline from 2023.
- Ptc Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$46.9M, a 36.9% decline from 2022.
- Ptc Therapeutics, Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$34.3M, a 9192% decline from 2021.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)